Shows / The Top Line

The Top Line
Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.
The show, from its episodes
No episode notes yet. Recurring topics, people and starter picks will appear when notes are available.
Typical episode length
19m · median of 129 episodes with a known length
Solo / guest format
Unknown — existing notes name people mentioned, but do not identify hosts or guests.
Recurring topics
No recurring topics established yet.
Recurring people
No recurring people established yet.
Start here
No starter picks yet — no published episodes with audio and a recorded notes hook.
Episodes
The Top LineDigital Twins: Advancing Clinical Evidence Strategy (Sponsored)
Patient digital twins give life sciences teams a framework for evaluating how an individual patient’s health trajectory could change under different…
The Top LineThe promise of molecular gates and what comes next
Gate Bioscience is betting that a decades-old biological mechanism could pave the way for a new class of medicines. The biotech is developing small molecules…
The Top LineHow Smarter Healthcare Environments Improve Patient Experience (Sponsored)
Patient experience is shaped by more than clinical care. It begins with transportation, parking and wayfinding, and continues through check-in, the patient…
The Top LineUse Kidney Genetics to Strengthen Clinical Trial Design (Sponsored)
Broad chronic kidney disease labels can obscure distinct biology, complicating patient selection, progression assumptions and treatment-signal interpretation…
The Top LineWhen China Fits a Global Clinical Development Strategy (Sponsored)
China can play several roles in a global clinical development program, from supporting a capital-efficient proof-of-concept study to contributing evidence…
The Top LineThere's more than one way to build a biotech
As biotech companies continue to navigate a challenging funding environment, Axiom Biosciences is taking an unconventional approach to raising capital and…
The Top LineWhen drug development gets personal
For nearly three decades, Jigar Raythatha has helped build biotech companies and bring new medicines to patients. But in 2023, the Third Rock Ventures partner…
The Top LineHow AI turns field conversations into actionable insights (Sponsored)
Life science field teams are a major source of customer insight, but growing complexity, limited HCP access and expanding omnichannel demands can make it…
The Top LineGSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing
In this week's episode of "The Top Line," we're covering a pair of FDA approvals for GSK, an antibody-drug conjugate pact worth up to $15 billion and the…
The Top LineInside Teva's Weltruza launch and Novo's GLP-1 strategy
In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical…
The Top LineThe Next Chapter for AI in Clinical Trials [Sponsored]
Clinical AI is moving from systems that predict and summarize toward agents that can help execute parts of a workflow. In this sponsored episode of The Top…
The Top LineHow AI could improve clinical trial decision-making (Sponsored)
What if clinical development teams could evaluate potential trial outcomes before a study reaches patients? In this sponsored episode of The Top Line, host…
The Top LineHow we picked the Fierce 15
What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to discuss what the winners…
The Top LineLocking in on pharma’s consumerization trend
With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. Now, the CEO of a buzzy pattern-hair-loss biotech…
The Top LineFierce Pharma Week: A look at the biggest trends, campaigns and conversations
Fierce Pharma Week brought thousands of people to Philadelphia for four days of conversations about pharma marketing, commercialization, medical affairs and…
The Top LineInside the growing world of biopharma prediction markets
Prediction markets are opening up new ways to bet on biopharma events, from clinical trial readouts to FDA approvals. But they also create a new set of risks…
The Top LineClinical trials reach a new automation inflection point (Sponsored)
Clinical development organizations are facing mounting pressure to do more with increasingly complex protocols, larger data sets and tighter timelines. While…
The Top LineThe future of RAS inhibitors
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field…
The Top LineThe people who stayed with the problem
The 2026 Fierce 50 includes people and organizations working on very different problems across biopharma and healthcare, from designing new proteins and…
The Top LineWhy Diagnostic-Driven Therapies Still Miss Eligible Patients (Sponsored)
The promise of precision medicine depends on more than scientific innovation. It also depends on whether eligible patients can be identified, tested and…
The Top LineMrBeast, Snapchat, AI and more: Pharma marketing’s pulse check
As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare…
The Top LineWhat did we learn from Big Pharma’s Q2 results?
Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to…
The Top LineHow consumerization is reshaping pharma marketing (Sponsored)
Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and…
The Top LineA genomics library for the AI era
Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a…
The Top LineThe next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
The future of patient support may depend less on how much data organizations collect and more on how effectively they connect, govern and activate it. In this…
The Top LineNovo Nordisk’s CFO on the oral Wegovy rollout and beyond
Novo Nordisk’s second-quarter earnings results this week were closely watched by analysts and investors eager to see whether the rollout of oral Wegovy…
The Top LineInside Noble’s connected approach to patient support (Sponsored)
The continued shift toward self-administered therapies is changing how pharmaceutical companies think about patient support. While access and affordability…
The Top LinePsychedelics, peptides and GLP-1s
Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? This week on…
The Top LineGSK’s first lung cancer approval, a new IPO path and more
This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the…
The Top LineWhy modern clinical trials need a finance-first strategy (Sponsored)
Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a…
The Top Line5 emerging biotech hubs
Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant…
The Top LineOperating at the speed of science: The new medical affairs playbook (Sponsored)
Medical affairs is at an inflection point. As science advances and healthcare professionals gain access to information in real time, medical teams face a…
The Top LineDecision readiness is the next AI advantage (Sponsored)
AI is reshaping how organizations compete, but more data and more tools do not automatically lead to better decisions. In this episode of The Top Line, Justin…
The Top LineA $10B deal, China trial scrutiny and highlights from ADA 2026
This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific…
The Top LineThe deal before the deal
Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week…
The Top LineFDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how…
The Top LineIpsen R&D chief on pipeline discipline, partnerships and 2026 milestones
In this episode of “The Top Line,” recorded on site at Fierce Biotech Week in Boston, Fierce’s Ayla Ellison sits down with Christelle Huguet…
The Top LineWhy MRD is becoming central to oncology drug development (Sponsored)
In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or…
The Top LineBehind the headlines of ASCO 2026
Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s annual meeting for a weekend of…
The Top LineMesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
High‑risk MDS and AML continue to challenge clinicians, with limited durable responses and few options for older or treatment‑refractory patients. In this…
The Top LineBoston, China and the future of biotech
Boston remains biotech's most influential hub, but the questions facing the region are increasingly global. Recorded live at Fierce Biotech Week in Boston…
The Top LineWhy direct-to-patient is the future of pharma access (Sponsored)
Direct-to-patient models are no longer an experiment - they're becoming a critical part of the modern prescription journey. In this sponsored episode of The…
The Top LineBioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder…
The Top LineDesigning an agentic, future‑ready tech roadmap for emerging pharma (Sponsored)
Emerging pharma organizations face unique technology challenges as they prepare for launch. Expectations for AI-enabled decision-making continue to rise, even…
The Top LineHealth execs persevere in new policy landscape
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and healthcare…
The Top LineRevisiting Pharma’s tariff reality
After months of mixed messaging from the White House, the pharmaceutical industry has gained more clarity on the second Trump administration’s import…
The Top LineSetting a new standard in prefillable syringe systems (Sponsored)
In this sponsored episode of The Top Line, host Kelly Hogan speaks with Dr. Bettine Boltres, director of scientific affairs, integrated systems at West…
The Top LineScaling theranostics through access, safety and trust (Sponsored)
Theranostics is transforming cancer care, but scaling these treatments requires overcoming operational and workforce challenges. In this episode of The Top…
The Top LineA pivotal time for an RNA pioneer
It’s a pivotal year for RNA therapeutics pioneer Ionis Pharmaceuticals. After transitioning from a partnering model to a full-ownership strategy…
The Top LineAccelerating clinical trials with precision logistics (Sponsored)
Speed, precision, and visibility are critical to clinical trial success, and logistics plays a central role in delivering all three. In this interview…
The Top LineCan Trump’s deal with the UK become a model for similar drug price agreements?
President Donald Trump has struck a deal with the UK that exempts prescription drugs imported to the United States from tariffs for three years. In exchange…
The Top LineBiomarkers are reshaping oncology trial design (Sponsored)
Biomarkers are playing an increasingly critical role in shaping the future of oncology trials—and the pace of innovation is accelerating. In this…
The Top LineAI brings precision to pharma content decisions (Sponsored)
Artificial intelligence is increasingly shaping how pharma companies approach content strategy and decision-making. In this episode of The Top Line, Kristen…
The Top LineFixing failed spray-dried formulations faster (Sponsored)
Spray-dried dispersions are widely used, but they do not always deliver expected results. In this sponsored episode of The Top Line, host Stephanie Butler…
The Top LineRoivant’s CEO thinks China is a ‘red herring’
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline…
The Top LineThe top 10 pharma R&D budgets of 2025
The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which companies are…
The Top LineAn update on the pharma industry’s reshoring effort
After a wave of high-profile pledges to bring pharmaceutical manufacturing back to the United States, a clearer picture of what reshoring actually looks like…
The Top LinePulse check on Lilly's GLP-1 fortunes
While Lilly’s position in the obesity market and wider GLP-1 space has remained largely unshakeable in recent months, a crack in the company’s…
The Top LineAvoiding 11th hour surprises in clinical trials (Sponsored)
In this episode of The Top Line, host Chris Hayden speaks with Olive McCormick, Head of Quality and Qualified Person at Almac Clinical Services about why…
The Top LineWhat Xaira is building after its $1B fundraise
Since Xaira’s eye-popping $1 billion fundraise in 2024, the company has said relatively little in public. That’s made it one of biotech’s…